Mazdutide
InvestigationalAlso known as: IBI362, LY3305677, Innovent/Lilly GLP-1/glucagon
Metabolic & Weight ManagementLast reviewed: April 28, 2026
A GLP-1/glucagon dual receptor agonist co-developed by Innovent Biologics and Eli Lilly. Mazdutide has shown strong weight loss results in Chinese clinical populations, with Phase 3 data showing up to 17.4% weight loss at 48 weeks. It received approval in China in late 2025 for obesity treatment, making it one of the first dual agonists to reach market anywhere in the world.
Mechanism of Action
Dual agonism of GLP-1 and glucagon receptors, similar to survodutide and pemvidutide. GLP-1 activation suppresses appetite and slows gastric emptying. Glucagon activation increases energy expenditure and hepatic fat oxidation. The dual mechanism targets both sides of the energy balance equation.
Common Uses
- Weight management (approved in China)
- Type 2 diabetes (investigational)
- Metabolic syndrome
Known Risks
- GI side effects (nausea, vomiting, diarrhea)
- Not yet approved outside China
- Potential blood sugar effects from glucagon component
- Long-term safety data still accumulating
Regulatory Status
Approved in China (late 2025) for obesity. Not yet submitted to FDA. Global Phase 3 trials ongoing. Represents the first approved GLP-1/glucagon dual agonist globally. US regulatory pathway unclear — may require separate US clinical program.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
6 mg or 9 mg (approved doses in China)
Frequency
Once weekly
Cycle Length
Ongoing
Currently available only in China. Not available in the US or Europe. The approval in China provides real-world safety and efficacy data that will inform global regulatory submissions. Check clinicaltrials.gov for any US-based trials.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.